News - Valeant Pharmaceuticals, Genito-urinary

Filter

Popular Filters

1 to 25 of 90 results

US FDA approves NDA from Actavis and Valeant

US FDA approves NDA from Actavis and Valeant

26-03-2014

US generics major Actavis and Canada’s Valeant Pharmaceuticals said that the US Food and Drug Administration…

ActavisCanadaGenericsMetronidazolePharmaceuticalRegulationUSAValeant PharmaceuticalsWomen's Health

Valeant Pharma returns to profit, boosted by B&L acquisition

27-02-2014

Canadian drugmaker Valeant Pharmaceuticals International has announces fourth quarter financial results…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio

03-02-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Teva launches authorized generic of Detrol in USA

Teva launches authorized generic of Detrol in USA

04-01-2014

Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, says it has launched…

Detrol LAGenericsGenito-urinaryMarkets & MarketingNorth AmericaPfizerTeva Pharmaceutical IndustriesUSA

Patent settlements for Pfizer/Teva and Mylan/Eisai

Patent settlements for Pfizer/Teva and Mylan/Eisai

18-12-2013

US pharma behemoth Pfizer says it has settled its long-standing litigation against a US subsidiary of…

Banner PharmacapsEisaiGenericsLegalMen's HealthMylan LaboratoriesNorth AmericaOncologyPatentsPfizerTargretinTeva Pharmaceutical IndustriesValeant PharmaceuticalsViagra

Positive top-line Ph III results with ceftolozane/tazobactam in cUTI

25-11-2013

US biopharma company Cubist Pharmaceuticals has revealed positive top-line results from its pivotal Phase…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsGenito-urinaryPharmaceuticalResearchtazobactam

Valeant agrees $142.5 million settlement with Anacor

28-10-2013

Anacor Pharmaceuticals says it has entered into a $142,5 million settlement agreement with Canada-based…

Anacor PharmaceuticalsFinancialLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Anacor Pharma awarded $100 million damages

18-10-2013

Anacor Pharmaceuticals says that the arbitrator appointed to resolve its dispute with Canada-based Valeant…

Anacor PharmaceuticalsLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

SOBI gains rights to distribute Ravicti in Middle East

01-10-2013

Swedish Orphan Biovitrum says Hyperion Therapeutics has granted it exclusive rights to distribute its…

Genito-urinaryHyperion TherapeuticsLicensingPharmaceuticalRavictiRest of the WorldSobiSwedish Orphan Biovitrum

UK MHRA licenses Allergan's Botox for use in patients with overactive bladder

11-09-2013

Botox (botulinum toxin type A), from US drugmaker Allergan (NYSE: AGN), has been licensed by the UK Medicines…

AllerganBotoxEuropeGenito-urinaryPharmaceuticalRegulation

Valeant Pharma beats forecasts, turns in profit

07-08-2013

Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) announced second quarter financial…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Valeant confirms plan to acquire Bausch & Lomb in a $8.7 billion transaction

28-05-2013

Following speculation ahead of the extended holiday weekend, acquisitive Canadian drugmaker Valeant Pharmaceuticals…

Bausch & LombMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

Netherlands first to approve Astellas' Vesomni

23-05-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says that the Dutch Medicines…

Astellas PharmaEuropeGenito-urinaryPharmaceuticalRegulationVesomni

NovaBay Pharmaceuticals: tuning in for a crescendo of data, say analysts

13-05-2013

US biotech firm NovaBay Pharmaceutical's (Nasdaq: NBY) first-quarter 2013 results set the scene for a…

Antibiotics and Infectious diseasesauricloseneBiotechnologyFinancialGenito-urinaryNovaBay PharmaceuticalNVC-422OphthalmicsResearch

Drais Pharma to develop third Astellas compound through Tacurion

08-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into…

ASP7035Astellas PharmaDrais PharmaceutialsGenito-urinaryLicensingPharmaceuticalResearchTacurion

Actavis and Valeant report first quarter 2013 results

02-05-2013

US generics drug major Actavis (NYSE: ACT) and Canada's Valeant Pharmaceuticals (TSX: VRX) both presented…

ActavisFinancialGenericsValeant Pharmaceuticals

Auxilium Pharma acquires Actient in $585 million deal

29-04-2013

Specialty drugmaker Auxilium Pharmaceuticals (Nasdaq: AUXL) says that it has completed the acquisition…

Actient PharmaAuxilium PharmaceuticalsGenito-urinaryMen's HealthMergers & AcquisitionsPharmaceutical

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?

29-04-2013

US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Positive data expected for RedHill Biopharma's Crohn's disease candidate

22-04-2013

Analysts at Roth Capital Partners have launched coverage of Israel-based specialty pharma company RedHill…

FinancialGenito-urinaryPharmaceuticalRBH-104RedHill BiopharmaResearch

Actavis settles with Valeant to launch generic Ziana and Zyclara in USA

11-04-2013

US generics drug major Actavis (NYSE: ACT) has reached settlement agreements with Medicis Pharmaceutical,…

ActavisGenericsMarkets & MarketingNorth AmericaPatentsValeant PharmaceuticalsZiana GelZyclara

1 to 25 of 90 results

Back to top